Hungary's Health Ministry on Sputnik V's Twitter account

26 April 2021

The government of Hungary, the first European Union country to start using the Russia-developed COVID-19 vaccine Sputnik V, released its latest data on safety and efficacy across five vaccines, which has been circulated by The Russian Direct Investment Fund (RDIF).

Sputnik V has the best safety (7-32 times fewer deaths cases) and efficacy (2-7 times fewer COVID infections) per 100,000 vaccinated, it noted.

Sputnik V demonstrates the best safety profile among other jabs in Hungary
Based on official data from the Government of Hungary after the 2nd shot between December 26th, 2020 and April 20th, 2021

Vaccine	No of infections per 100,000 vaccinations	No of death per 100,000 vaccinations	No of infections and death per 100,000 vaccinations of OTHER JABS compared to SPUTNIK V (x times)
	No of infections per 100,000 vaccinations	No of death per 100,000 vaccinations	Infections	Deaths
Sputnik V	95	1	-	-
AstraZeneca	700	7	7x	7x
SinoPharm	356	16	4x	16x
Moderna	177	20	2x	20x
Pfizer/BioNTech	555	32	6x	32x

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK